This summer, Pulse welcomed: Friedreichs Ataxia Research Alliance (FARA), a non-profit organization dedicated to curing Friedreich’s Ataxia and the related ataxias. The FARA registry will facilitate dialogue between the public and scientific communities globally and promote information exchange that drives medical advances.
Myonexus Therapeutics, a clinical stage gene therapy company focused on treating distinct forms of Limb-Girdle Muscular Dystrophy, and Pulse Infoframe signed a multi-year agreement encompassing a multitude of Pulse products and services, including a global registry focused on identifying new treatment options for this devastating illness. These new initiatives demonstrate Pulse’s commitment to the rare disease and cancer communities, contributing what we can toward cures and quality of life improvement.
This story first appeared in our February 2019 newsletter. Get Pulse Infoframe news delivered to your inbox. Email us to sign up today.
